Mesoblast (ASX:MSB) jumped around +8% in morning trades to $2.80 a pop as it continues to move past moments of investor disappointment through the calendar year – particularly after it posted a -US$100 million loss in late August.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Boosting sentiment on Tuesday is news from the company that its flagship Ryoncil product, more or less a stem cell treatment, has seen revenues increase 66% in the second quarter after a recent launch – reflecting a figure of US$21.9M.
“We expect adoption to be further enhanced following the permanent J-Code assigned by Centers for Medicare and Medicaid Services (CMS), which became active October 1,” company chief Dr Silviu Itescu said.
J-Codes are US FDA-standardised codes for identifying drugs. Presumably, having a J-Code makes one’s product more likely to be bought.
The Tuesday uptick also follows an Australian market sentiment that didn’t really care when MSB kicked off early-stage works on kids with graft-host disease in March and even yawned at an FDA win back in May.
(At the time, I asked if the oft-hyped company was becoming just another DroneShield – that didn’t age too well, looking at what DRO’s done since.)
Of course, Mesoblast was perhaps always most a victim of Donald Trump’s April 2 shock of all things; the company’s erstwhile “belief” that it wouldn’t be affected by global tariffs has, so far, proved to be true.
MSB last traded at $2.81/sh today.
Join the discussion: See what HotCopper users are saying about Mesoblast Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.